Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Rosuvastatin When Coadministered With MK-4646 in Healthy Participants
NCT07785830Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of MK-4646 in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Infinity of Rosuvastatin at 72 hours and Maximum Plasma Concentration of Rosuvastatin at 72 hours. Started Sep 2026; status: active, not recruiting.
02
Drugs
MK-4646
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07785830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07785830.